VIDA Lung AI provides data-driven, AI-powered clinical trial imaging services. Their platform enables exceptional imaging data quality and efficient site operations, offering services such as image analysis and site management to support drug development and clinical trials.
VIDA, a clinical imaging intelligence company, focuses on streamlining the drug development and clinical trial process using AI-powered digital biomarker solutions. Key offerings include the VIDA Intelligence Platform, which facilitates high-quality imaging data from over 1,500 global sites, helping biopharma sponsors save millions in drug development costs.
VIDA serves multiple therapeutic areas, expanding its AI-powered imaging biomarkers across:
VIDA collaborates with Polarean for advanced MRI solutions and RAYUS Radiology for decentralized clinical trials, integrating AI analysis across various modalities and therapeutics.
Ensuring data privacy and security, VIDA complies with HIPAA standards and ISO certifications, using AES256-bit encryption to protect patient information.
The company is led by experienced professionals like CEO Dr. Susan Wood, and continues to gain recognition and grow with strategic partnerships. Recent appointments and market expansions, including entry into Japan with Clairvo, underscore committed growth.
VIDA presents regular webinars featuring experts on topics such as COPD studies and digital biomarkers in clinical trials, aiming to educate and inform the clinical research community.
VIDA's offerings aim to modernize and enhance the efficiency of clinical trials, supporting pharmaceutical innovators in drug development processes while maintaining strict compliance with data privacy regulations.